Clinical Trial Update: Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1 [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial evaluating a combination of Vitamin D, telaprevir, peginterferon, and ribavirin for Hepatitis C genotype 1 has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Peginterferon (Pegylated interferon)
• Ribavirin (ribavirin)
• Telaprevir (telaprevir)
• Vitamin D (Cholecalciferol)

Snippet

Sponsor: Timothy Morgan, MD | Conditions: Hepatitis C | Phase 2, Phase 3 | Status: WITHDRAWN